Can tocotrienol reduce time to the first serious adverse event during treatment with FOLFOXIRI for colorectal cancer?

Louise Raunkilde Larsen, Torben Frøstrup Hansen, Anders Jakobsen, Lars Henrik Jensen

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Annals of Oncology
Vol/bind	30
Udgave nummer	Suppl. 5
Sider (fra-til)	v871
Antal sider	1
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdz394.026
Status	Udgivet - 2019
Begivenhed	ESMO Congress 2019 : Translating science into better cancer patient care - Barcelona, Spanien Varighed: 27. sep. 2019 → 1. okt. 2019 https://www.esmo.org/Conferences/Past-Conferences/ESMO-Congress-2019

Konference	ESMO Congress 2019
Land/Område	Spanien
By	Barcelona
Periode	27/09/2019 → 01/10/2019
Internetadresse	https://www.esmo.org/Conferences/Past-Conferences/ESMO-Congress-2019

Dokumenter og links

@article{d822f78eed5a432f9f99ae5ea6c000c5,

title = "Can tocotrienol reduce time to the first serious adverse event during treatment with FOLFOXIRI for colorectal cancer?",

author = "{Raunkilde Larsen}, Louise and Hansen, {Torben Fr{\o}strup} and Anders Jakobsen and Jensen, {Lars Henrik}",

year = "2019",

doi = "10.1093/annonc/mdz394.026",

language = "English",

volume = "30",

pages = "v871",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "Suppl. 5",